<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19641" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clozapine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haidary</surname>
            <given-names>Habib A.</given-names>
          </name>
          <aff>Kern Medical Center/American University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padhy</surname>
            <given-names>Ranjit K.</given-names>
          </name>
          <aff>UCLA - Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Habib Haidary declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ranjit Padhy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19641.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Clozapine is an FDA-approved atypical antipsychotic medication for treatment-resistant schizophrenia. Clozapine is not the first-line drug of choice due to its range of adverse effects, making compliance an issue for many patients. However, clozapine also has some advantages, including lowering the risk of suicide and tardive dyskinesia and fewer relapses. Regarding suicide risk, clozapine has been demonstrated to reduce suicidal behavior even in non-treatment-resistant schizophrenia and patients with schizoaffective disorder. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of clozapine pertinent for members of the interprofessional team where this agent is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for clozapine therapy based on treatment-resistant schizophrenia or recurrent suicidal behavior.</p></list-item><list-item><p>Differentiate between the unique pharmacological profile of clozapine and other antipsychotic medications, including its superior efficacy in treatment-resistant cases.</p></list-item><list-item><p>Assess treatment response and optimize the dosage of clozapine to achieve the desired therapeutic outcomes while minimizing adverse effects.</p></list-item><list-item><p>Collaborate with other interprofessional healthcare team members, such as pharmacists and laboratory staff, to ensure the safe and effective use of clozapine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19641&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19641">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19641.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Clozapine is an FDA-approved atypical antipsychotic drug for treatment-resistant schizophrenia.<xref ref-type="bibr" rid="article-19641.r1">[1]</xref>&#x000a0;The definition of treatment-resistant schizophrenia is persistent or moderate delusions or hallucinations after failing&#x000a0;two trials of antipsychotic medicines.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;Clozapine&#x000a0;is also approved for schizophrenia-associated suicide prevention. Since its creation,&#x000a0;clozapine has been the drug of choice for treatment-resistant schizophrenia despite its many adverse effects.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Clozapine is not the first-line drug of choice due to its range of adverse effects, making compliance an issue for many patients.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p>Clozapine was first synthesized in 1956 in many European countries, including Switzerland, Austria, West Germany, and Finland.<xref ref-type="bibr" rid="article-19641.r1">[1]</xref><xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;Concurrent studies in the United States led to reports of death due to cases of agranulocytosis, taking clozapine off the market for a long time.<xref ref-type="bibr" rid="article-19641.r1">[1]</xref>&#x000a0;</p>
        <p>A pivotal study known as the US Clozaril Study showed the efficacy of clozapine over chlorpromazine in a 6-week trial of patients who failed to respond to&#x000a0;three previous antipsychotic drugs.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;The study results ultimately led to the FDA approval for treatment-resistant schizophrenia.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;A meta-analysis done in 2018 showed that clozapine might be more effective than other antipsychotics even when used as a first- or second-line treatment.<xref ref-type="bibr" rid="article-19641.r4">[4]</xref>&#x000a0;</p>
        <p>The&#x000a0;American Psychiatry Association&#x000a0;guidelines recommend that patients with treatment-resistant schizophrenia with an increased&#x000a0;risk for suicide should be treated with clozapine.<xref ref-type="bibr" rid="article-19641.r5">[5]</xref></p>
        <p>Other advantages of clozapine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lower risk of suicide (clozapine has&#x000a0;been shown to reduce suicidal behavior even in patients with non-treatment-resistant schizophrenia and schizoaffective disorder)[2]</p>
          </list-item>
          <list-item>
            <p>Lower risk for tardive dyskinesia</p>
          </list-item>
          <list-item>
            <p>Improvement of cognition, which leads to improved quality of life</p>
          </list-item>
          <list-item>
            <p>Decreased relapse</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19641.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Clozapine is part of a group of drugs known as second-generation antipsychotics or atypical antipsychotics.&#x000a0;Antipsychotic drugs are vital in treating the core symptoms of schizophrenia: hallucinations and delusions.<xref ref-type="bibr" rid="article-19641.r6">[6]</xref>&#x000a0;As an atypical antipsychotic, clozapine is an antagonist to dopamine and serotonin receptors.&#x000a0;Clozapine binds to the dopamine D4 receptor with a higher affinity than the dopamine D2 receptor, contributing to decreased&#x000a0;adverse events and extrapyramidal symptoms.&#x000a0;Clozapine is a partial 5-HT1A agonist that reduces adverse&#x000a0;and extrapyramidal symptoms and a muscarinic M1,&#x000a0;M2, M3, M5, histamine, and alpha-1 adrenergic-receptor antagonist.&#x000a0;Norclozapine, the metabolite of clozapine, actively works on the M1 and M4 receptors.<xref ref-type="bibr" rid="article-19641.r1">[1]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Clozapine tablets are bioequivalent to a clozapine solution. The peak plasma concentrations are attained at 2.5 hours(1 to 6 hours). Food does not seem to influence the bioavailability of clozapine; clozapine may be administered with or without food.</p>
        <p><bold>Distribution:&#x000a0;</bold>Clozapine exhibits approximately 97% plasma protein binding. Clozapine is transported across the blood-brain barrier.</p>
        <p><bold>Metabolism: </bold>The uptake&#x000a0;of clozapine in the liver is mediated by SLC22A1, SLC22A2, and SLC22A3 (solute carrier (SLC) family). Clozapine is extensively metabolized in the liver by cytochrome P450 isozymes, particularly CYP1A2, CYP2D6, and CYP3A4. CYP3A4 and CYP1A2 are the major enzymes responsible for demethylation, with CYP2D6 playing a minor role. The desmethyl-norclozapine is an active metabolite of clozapine.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref><xref ref-type="bibr" rid="article-19641.r7">[7]</xref></p>
        <p><bold>Excretion: </bold>The mean elimination half-life ranges from 8 to 12 hours; the elimination half-life increases after multiple dosing. Approximately 50% of clozapine is excreted in the urine and 30% in the feces.<xref ref-type="bibr" rid="article-19641.r8">[8]</xref></p>
      </sec>
      <sec id="article-19641.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Healthcare Providers must apply and receive certification in the Clozapine REMS program to prescribe clozapine for outpatient use. To receive treatment, a patient must be enrolled in the clozapine REMS registry by a certified clinician. In addition, pharmacies and pharmacists must obtain certification through Clozapine REMS to receive clozapine and dispense it to patients. All of these actions can be done online through the website www.clozapineREMS.com.</p>
        <p>Clozapine is available as oral tablets, orally disintegrating tablets, and oral suspension in the following strength. The choice of dosage form depends on patient acceptability and tolerability.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablet dosages of 25 mg, 50 mg, 100 mg, and 200 mg</p>
          </list-item>
          <list-item>
            <p>Orally disintegrating tablet dosages of 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg</p>
          </list-item>
          <list-item>
            <p>Oral suspension dosage of&#x000a0;50 mg/mL (100 mL)</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-resistant schizophrenia and schizophrenia-associated suicide prevention - 150 to 300 mg orally twice daily. Start 12.5 mg daily or twice daily, and increase by 25 to 50 mg daily to target 300 to 450 mg daily in divided doses by day 14. Then, increase by up to 100 mg daily every 3 to 7 days.</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-resistant schizophrenia and&#x000a0;schizophrenia-associated suicide prevention - 125 to&#x000a0;475 mg orally daily in 2 or 3 divided doses.&#x000a0;Start 12.5 mg daily or twice daily, and increase by&#x000a0;12.5 to&#x000a0;25 mg daily every 3 to 5 days as tolerated. The maximum&#x000a0;dose is 700 mg daily. If divided doses are not equal, give the larger dose at bedtime.</p>
          </list-item>
        </list>
        <p>According to the FDA, clozapine's maximum recommended dosage is up to 900 mg daily.&#x000a0;The average dose is 300 mg for women and 400 mg daily for men.&#x000a0;Slow titration is essential for reducing many side effects associated with clozapine.<xref ref-type="bibr" rid="article-19641.r9">[9]</xref>&#x000a0;With the persistent partial response, clozapine may be augmented with ECT to increase efficacy.<xref ref-type="bibr" rid="article-19641.r9">[9]</xref><xref ref-type="bibr" rid="article-19641.r10">[10]</xref>&#x000a0;Other methods of augmentation include lamotrigine and other antipsychotics.<xref ref-type="bibr" rid="article-19641.r9">[9]</xref></p>
        <p>Look-alike/sound-alike&#x000a0;(LASA): According to the Institute for Safe Medication Practices (ISMP), clozapine may be confused with clonazepam or clonidine. Prescribe and dispense with caution.<xref ref-type="bibr" rid="article-19641.r11">[11]</xref><xref ref-type="bibr" rid="article-19641.r12">[12]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The manufacturer's labeling provides no dosage adjustment recommendation; however, it suggests dose reductions in patients with significant hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> The manufacturer's labeling provides no dosage adjustment recommendation; however, it suggests dose reductions in patients with significant renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Women between 18 to 45 years of age and exposed to clozapine during pregnancy should be enrolled in&#x000a0;the Atypical Antipsychotics Pregnancy Registry by their healthcare providers. (website: womensmentalhealth.org/pregnancyregistry). Clozapine is an FDA pregnancy category B medicine. Cases reports of shoulder dystocia, atrial septum defect, seizures, and floppy infant syndrome have been reported. Use with caution.<xref ref-type="bibr" rid="article-19641.r13">[13]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Since clozapine use is not studied&#x000a0;during breastfeeding, and some case reports of sedation and adverse hematologic effects in breastfed infants are in the literature, alternative medicine is advised.&#x000a0;If the infant is exposed to clozapine via breastfeeding, closely monitor the infant for excessive sedation and white blood cell count. Some expert panel recommends against breastfeeding if women require clozapine while lactating.<xref ref-type="bibr" rid="article-19641.r14">[14]</xref></p>
        <p><bold>Potentially inappropriate medication for older patients: </bold>According to the American Geriatric Society(AGS) beers criteria, clozapine has anticholinergic properties, and its use should be considered only for FDA-approved conditions.<xref ref-type="bibr" rid="article-19641.r15">[15]</xref></p>
        <p><bold>Pharmacogenomic considerations:</bold>&#x000a0;Dose reduction may be&#x000a0;required&#x000a0;in&#x000a0;patients&#x000a0;who are CYP2D6-poor&#x000a0;metabolizers.<xref ref-type="bibr" rid="article-19641.r16">[16]</xref></p>
      </sec>
      <sec id="article-19641.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Agranulocytosis</bold>
</p>
        <p>The risk of developing agranulocytosis is around 1% in patients who take clozapine, which may&#x000a0;occur independent of dosing.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref><xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Most cases occur early in the treatment, within six weeks to six months, and require extensive monitoring of blood absolute neutrophil counts.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;</p>
        <p>The definition of neutropenia is an ANC level below 1500/mm,&#x000a0;and agranulocytosis is an ANC level below 500/mm. Many have tried to explain the link between clozapine and agranulocytosis by attributing this adverse effect to drug interactions with the immune system and genetic predisposition.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;</p>
        <p>A study in 2015 looked into the benefits of pharmacogenetic testing and how it may affect monitoring in patients at risk for clozapine-induced agranulocytosis.<xref ref-type="bibr" rid="article-19641.r17">[17]</xref>&#x000a0;The study suggested that patients with a lower genetic risk may benefit from a more relaxed hematological monitoring schedule.<xref ref-type="bibr" rid="article-19641.r17">[17]</xref>&#x000a0;Risk factors include old age, female, genetics, and concurrent treatment with other drugs known to cause agranulocytosis.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;</p>
        <p>Clinicians must place patients taking clozapine on a national registry.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;Granulocyte colony-stimulating&#x000a0;factor may&#x000a0;be an option&#x000a0;to&#x000a0;increase levels of white blood cells.<xref ref-type="bibr" rid="article-19641.r9">[9]</xref></p>
        <p>
<bold>Myocarditis</bold>
</p>
        <p>Clozapine-induced myocarditis is a rare complication, affecting less than 3% of patients. This lethal dose-independent side effect appears more frequently during the first four weeks of treatment. In these patients, signs and symptoms of myocarditis may vary from having a flu-like illness to respiratory and cardiovascular symptoms.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Some clozapine-induced myocarditis cases may even present atypically without any symptoms, leading to higher fatality rates.&#x000a0;Risk factors include rapid titration of the drug, metabolic side effects of clozapine, concurrent use of selective serotonin reuptake inhibitors, and illicit substances.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Treatment includes immediate clozapine cessation, which may resolve the case.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p>
<bold>Metabolic Syndrome</bold>
</p>
        <p>Clozapine is associated with significant weight gain, type 2 diabetes, diabetic ketoacidosis, and increased lipid levels due to increased insulin resistance.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref>&#x000a0;Both clozapine and olanzapine have higher metabolic side effects than the other atypical and typical antipsychotics due to their high affinity for serotonin 5-HT2C receptors.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref><xref ref-type="bibr" rid="article-19641.r6">[6]</xref>&#x000a0;Clinicians must note that other factors, including poor diet and a sedentary lifestyle, may contribute to the development of metabolic syndrome.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;</p>
        <p>The American Heart Association defines metabolic syndrome as increased weight, dyslipidemia, increased blood pressure, increased glucose intolerance, increased proinflammatory, and prothrombic states.<xref ref-type="bibr" rid="article-19641.r6">[6]</xref>&#x000a0;The development of DKA is one of the serious side effects of clozapine, having a higher mortality rate than agranulocytosis.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Recommendations include counseling the patient on proper diet, exercise, and other drugs like metformin and orlistat to reduce the metabolic effects of clozapine.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref><xref ref-type="bibr" rid="article-19641.r2">[2]</xref></p>
        <p>
<bold>Seizures</bold>
</p>
        <p>Clozapine may lower the seizure threshold in&#x000a0;patients with epilepsy.&#x000a0;The risk is usually dose-dependent, around 1% to 6%, especially with rapid titration, and might be more prevalent in younger patients. This side effect may appear at any stage of treatment.&#x000a0;Patients who experience a seizure while on clozapine may benefit from adding an anti-epileptic&#x000a0;such as valproic acid.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p>
<bold>Excessive Salivation</bold>
</p>
        <p>Sialorrhea is a dose-dependent and benign condition that may bother some patients.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;One risk of excessive salivation is aspiration pneumonia.<xref ref-type="bibr" rid="article-19641.r18">[18]</xref></p>
        <p>
<bold>Pulmonary Embolism</bold>
</p>
        <p>A recent study&#x000a0;comparing clozapine to several other antipsychotics&#x000a0;showed it to be the only drug to increase platelet adhesion and aggregation.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref> The risk seems higher in&#x000a0;older patients and pregnant women taking high doses.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;Many studies have found this link dose-independent, highly lethal, and&#x000a0;demonstrate early onset.<xref ref-type="bibr" rid="article-19641.r19">[19]</xref></p>
        <p>
<bold>Constipation</bold>
</p>
        <p>Cholinergic and serotonergic properties of clozapine may affect the gastrointestinal system and lead to constipation or even ileus.&#x000a0;Constipation affects anywhere from 15% to 60% of all patients taking clozapine and is dose-dependent, making it one of the most common side effects.&#x000a0;In severe cases, constipation can progress to ileus, leading to obstruction and ischemia.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;</p>
        <p>One study suggests these cholinergic effects may even lead to dysphagia, which can progress to aspiration pneumonia, meaning gastric hypomotility may not be limited to the bowel.<xref ref-type="bibr" rid="article-19641.r18">[18]</xref>&#x000a0;Management includes adequate fluid intake, laxative or docusate use, and dose reduction.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p>
<bold>Neuroleptic Malignant Syndrome</bold>
</p>
        <p>Clinical manifestations include muscular rigidity, altered mental status, autonomic dysfunction, hyperthermia, and blood pressure fluctuation. Increased creatine phosphokinase levels, rhabdomyolysis, and acute kidney injury have been reported. Other laboratory abnormalities may include reduced serum iron levels, metabolic acidosis, and coagulopathy. Prompt discontinuation and supportive care of clozapine are required.<xref ref-type="bibr" rid="article-19641.r20">[20]</xref><xref ref-type="bibr" rid="article-19641.r21">[21]</xref><xref ref-type="bibr" rid="article-19641.r22">[22]</xref></p>
        <p>
<bold>Other</bold>
</p>
        <p>Other side effects may include orthostatic hypotension, sedation, tachycardia, sexual dysfunction, and urinary retention.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that may inhibit cytochrome CYP1A2, leading to increased levels of clozapine, include but are not limited to antifungals, oral contraceptives, fluvoxamine, ciprofloxacin, and caffeine disulfiram.&#x000a0;Drugs that may induce CYP1A2 include but are not limited to omeprazole, rifampicin, tobacco, phenytoin, and phenobarbital.</p>
          </list-item>
          <list-item>
            <p>Drugs that induce (carbamazepine and rifampicin) and inhibit (cimetidine and erythromycin, among others) CYP3A4 may also affect clozapine drug levels.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Tobacco may affect clozapine metabolism through CYP1A2; therefore, it is important to&#x000a0;monitor the blood levels and efficacy of clozapine when a patient smokes or abruptly stops.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>QTc prolongation has been reported with clozapine, especially in patients with electrolyte abnormalities.<xref ref-type="bibr" rid="article-19641.r23">[23]</xref>&#x000a0;Antipsychotic drugs like amisulpride, ziprasidone, risperidone, olanzapine, quetiapine, and haloperidol can prolong&#x000a0;QTc interval and&#x000a0;can lead to&#x000a0;Torsades de Pointes.<xref ref-type="bibr" rid="article-19641.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Antibiotics like macrolides (eg, erythromycin), linezolid, imipenem-cilastatin, moxifloxacin, and ceftriaxone can also prolong QTc interval. Use with caution.<xref ref-type="bibr" rid="article-19641.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Antiarrhythmic drugs, Class Ia antiarrhythmic agents (quinidine and procainamide), and class III antiarrhythmics (sotalol and amiodarone) prolong&#x000a0;QTc interval and increase the risk&#x000a0;of polymorphic ventricular tachycardia (TdP). Concurrent administration with clozapine may further increase the risk.<xref ref-type="bibr" rid="article-19641.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Methadone is associated with QTc prolongation in a dose-dependent&#x000a0;manner. Concurrent administration with clozapine requires close monitoring.<xref ref-type="bibr" rid="article-19641.r27">[27]</xref><xref ref-type="bibr" rid="article-19641.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19641.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Clozapine is contraindicated in patients with serious hypersensitivity reactions to clozapine or any component of the formulation.</p>
        <p>FDA states the following boxed warnings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neutropenia (due to the risk of agranulocytosis)</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension, bradycardia, and syncope</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Myocarditis&#x000a0;and mitral valve incompetence</p>
          </list-item>
          <list-item>
            <p>Increased mortality in dementia-related psychosis in elderly patients (risk of a cardiovascular event)<xref ref-type="bibr" rid="article-19641.r29">[29]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19641.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Serious adverse effects that require monitoring include but are not limited to the following:&#x000a0;</p>
        <p><bold>Agranulocytosis:&#x000a0;</bold>Weekly complete blood count (CBC) to measure ANC levels. ANC levels less than 1500 per mm indicate neutropenia. Levels less than 500 per mm indicate agranulocytosis.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref>&#x000a0;A complete blood count should be taken weekly for the first&#x000a0;6 months,&#x000a0;then every other week for the next&#x000a0;6 months.<xref ref-type="bibr" rid="article-19641.r1">[1]</xref>&#x000a0;A national registry is in place to monitor for safe use.<xref ref-type="bibr" rid="article-19641.r2">[2]</xref></p>
        <p><bold>Metabolic syndrome:&#x000a0;</bold>Diet and exercise, blood glucose levels.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p><bold>Cardiovascular:&#x000a0;</bold>Baseline troponin I or T levels, high sensitivity CRP levels, echocardiography, and BNP levels, as well as vitals and weekly laboratory testing of troponins, CRP, and BNP levels.<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p><bold>Seizure: </bold>EEG and clozapine blood levels&#x000a0;<xref ref-type="bibr" rid="article-19641.r3">[3]</xref></p>
        <p><bold>Clinical monitoring:&#x000a0;</bold>Monitor for clinical improvement in patients at each visit. The Clinical Global Impression&#x02013;Schizophrenia (CGI&#x02013;SCH) scale can assess the&#x000a0;treatment response in patients with schizophrenia.<xref ref-type="bibr" rid="article-19641.r30">[30]</xref></p>
      </sec>
      <sec id="article-19641.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The reported mortality rate of clozapine intoxication is approximately 12%.<xref ref-type="bibr" rid="article-19641.r31">[31]</xref>&#x000a0;A 36-year-old&#x000a0;man experienced rhabdomyolysis following an overdose of clozapine 125 mg tablets. After&#x000a0;5 days, the patient was discharged from the hospital when the creatinine kinase levels returned within normal range. Monitor creatinine kinase levels to diagnose possible rhabdomyolysis.<xref ref-type="bibr" rid="article-19641.r32">[32]</xref>&#x000a0;Another acute overdose in a 60-year-old&#x000a0;man reported venous thromboembolism and pulmonary embolism; therefore, it is essential to monitor patients initiated on clozapine who may be at an increased risk of thromboembolic events.<xref ref-type="bibr" rid="article-19641.r33">[33]</xref></p>
        <p>The common adverse events associated with clozapine overdose are&#x000a0;hypersalivation, tachycardia, hypotension, sedation, delirium, coma, respiratory depression, or failure. There are few reports of cardiac arrhythmias, aspiration pneumonia, and seizure. Fatality is reported at doses above 2500 mg; however, some patients recovered after ingesting 4000 mg of clozapine.</p>
        <p>
<bold>Management</bold>
</p>
        <p>There is a lack of a specific antidote to an overdose of clozapine. Monitor and maintain an airway, ventilation, cardiac status, and vital signs, and provide symptomatic and supportive measures. Consider the possibility of multiple-drug overdose and contact the Poison Control Center to report and get information on additional management (1-800-222-1222).</p>
      </sec>
      <sec id="article-19641.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clozapine, due to its many lethal adverse reactions, has become a drug that many clinicians are afraid to prescribe due to fear of patient safety. Psychiatrists prescribe clozapine in supervised settings to patients with a risk of suicide.&#x000a0;Nursing staff should monitor the patients for&#x000a0;compliance. Pharmacists should perform thorough medication reconciliation and report adverse effects to clinicians.&#x000a0;One of the most significant concerns for clozapine is the adverse effect of agranulocytosis, which requires cessation of therapy and hematology consultation. Serious infection resulting from agranulocytosis may require infectious disease consultation. Cardiologist input is crucial for myocarditis. Clozapine poisoning requires rapid stabilization by the critical care team and consultation medical toxicologist.</p>
        <p>The FDA has mandated a national registry to monitor weekly white blood cell count levels for anyone prescribed clozapine. There are many limitations to clozapine use, described in a systematic review looking at barriers to its use.&#x000a0;Barriers described in the study are the patient, the clinician, and health-system-related barriers. Patient barriers encompass noncompliance with weekly blood draws, intolerance to clozapine adverse effects, and the management complexities associated with multiple prescribed drugs.</p>
        <p>From the clinician's standpoint, barriers encompass inadequate experience and knowledge in prescribing clozapine, fear of side effects, non-adherence to guidelines, the necessity for intense monitoring, and perceptions of patient non-compliance; systemic issues involve insufficient resources like staffing and nurses, a shortage of beds, and service fragmentation. Addressing these challenges requires the implementation of point-of-care devices, educational interventions for both clinicians and patients, and shared decision-making, with the effectiveness of these solutions necessitating evaluation through controlled study designs.<xref ref-type="bibr" rid="article-19641.r34">[34]</xref> A collaborative healthcare team comprising clinicians, including psychiatric specialists and pharmacists, employing open communication, shared patient data, and collaborative treatment strategies, has the potential to enhance therapeutic efficacy and optimize treatment outcomes associated with clozapine therapy.</p>
      </sec>
      <sec id="article-19641.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19641&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19641">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19641/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19641">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19641.s11">
        <title>References</title>
        <ref id="article-19641.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St&#x00119;pnicki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kondej</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaczor</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Current Concepts and Treatments of Schizophrenia.</article-title>
            <source>Molecules</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>23</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">30127324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meltzer</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>Clozapine: balancing safety with superior antipsychotic efficacy.</article-title>
            <source>Clin Schizophr Relat Psychoses</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>134</fpage>
            <page-range>134-44</page-range>
            <pub-id pub-id-type="pmid">23006238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Berardis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rapini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Nicola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tomasetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valchera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Fabio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Nicola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serafini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vellante</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Orsolini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Giannantonio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2018</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>237</fpage>
            <page-range>237-256</page-range>
            <pub-id pub-id-type="pmid">29796248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okhuijsen-Pfeifer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huijsman</surname>
                <given-names>EAH</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>IEC</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Luykx</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-288</page-range>
            <pub-id pub-id-type="pmid">30218445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ijaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolea</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savovi&#x00107;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.</article-title>
            <source>BMC Psychiatry</source>
            <year>2018</year>
            <month>Sep</month>
            <day>03</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>275</fpage>
            <pub-id pub-id-type="pmid">30176844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorn</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>PharmGKB summary: clozapine pathway, pharmacokinetics.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>214</fpage>
            <page-range>214-222</page-range>
            <pub-id pub-id-type="pmid">30134346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geisler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeSanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fervaha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clozapine administration in clinical practice: once-daily versus divided dosing.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-40</page-range>
            <pub-id pub-id-type="pmid">27182769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Optimizing clozapine treatment.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-22</page-range>
            <pub-id pub-id-type="pmid">21534935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nucifora</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Woznica</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Cascella</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sawa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.</article-title>
            <source>Neurobiol Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>131</volume>
            <fpage>104257</fpage>
            <pub-id pub-id-type="pmid">30170114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grissinger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tall man letters are gaining wide acceptance.</article-title>
            <source>P T</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>132</fpage>
            <page-range>132-48</page-range>
            <pub-id pub-id-type="pmid">22605902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fenger-Gron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Skaarup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <collab>Danish Psychiatric Society</collab>
              <collab>Danish Society of Obstetrics and Gynecology</collab>
              <collab>Danish Paediatric Society</collab>
              <collab>Danish Society of Clinical Pharmacology</collab>
            </person-group>
            <article-title>Use of psychotropic drugs during pregnancy and breast-feeding.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2015</year>
            <issue>445</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">26344706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uguz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>244</fpage>
            <page-range>244-52</page-range>
            <pub-id pub-id-type="pmid">27028982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Clozapine Therapy and <italic>CYP</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2016</year>
            <month>6</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28520368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>DeLisi</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis.</article-title>
            <source>Curr Opin Psychiatry</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-408</page-range>
            <pub-id pub-id-type="pmid">29985178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurrera</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Clozapine-Associated Aspiration Pneumonia: Case Series and Review of the Literature: Reply.</article-title>
            <source>Psychosomatics</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <pub-id pub-id-type="pmid">30119837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarvaiya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lapitskaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dima</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clozapine-Associated Pulmonary Embolism: A High-Mortality, Dose-Independent and Early-Onset Adverse Effect.</article-title>
            <source>Am J Ther</source>
            <year>2018</year>
            <season>Jul/Aug</season>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>e434</fpage>
            <page-range>e434-e438</page-range>
            <pub-id pub-id-type="pmid">29985823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crisostomo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome associated with clozapine treatment.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-5</page-range>
            <pub-id pub-id-type="pmid">8556099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCaffrey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O&#x002bc;Murchu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krivoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerandel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>MacCabe</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gaughran</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2019</year>
            <season>Jul/Aug</season>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>372</fpage>
            <page-range>372-379</page-range>
            <pub-id pub-id-type="pmid">31205196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ware</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Feller</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic Malignant Syndrome: Diagnosis and Management.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2018</year>
            <month>Jan</month>
            <day>04</day>
            <volume>20</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29325237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Honer</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Procyshyn</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Clozapine, elevated heart rate and QTc prolongation.</article-title>
            <source>J Psychiatry Neurosci</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-72</page-range>
            <pub-id pub-id-type="pmid">29252168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urness</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Teehan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Physical Health and Drug Safety in Individuals with Schizophrenia.</article-title>
            <source>Can J Psychiatry</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>673</fpage>
            <page-range>673-683</page-range>
            <pub-id pub-id-type="pmid">28718324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>DKS</given-names>
              </name>
              <name>
                <surname>Obodozie-Ofoegbu</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Frei</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.</article-title>
            <source>Int J Med Sci</source>
            <year>2019</year>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>1018</fpage>
            <page-range>1018-1022</page-range>
            <pub-id pub-id-type="pmid">31341415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taira</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Opezzo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>H&#x000f6;cht</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular drugs inducing QT prolongation: facts and evidence.</article-title>
            <source>Curr Drug Saf</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">20210721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bart</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wyman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bart</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort.</article-title>
            <source>J Addict Med</source>
            <year>2017</year>
            <season>Nov/Dec</season>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>489</fpage>
            <page-range>489-493</page-range>
            <pub-id pub-id-type="pmid">28863009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovell</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Protus</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Saphire</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kale</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of QTc Interval Prolongation Among Patients With Cancer Using Enteral Methadone.</article-title>
            <source>Am J Hosp Palliat Care</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-184</page-range>
            <pub-id pub-id-type="pmid">30428683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dragoi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Radulescu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>N&#x00103;sui</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Varlas</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Trifu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.</article-title>
            <source>Brain Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <day>11</day>
            <volume>10</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">33187329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Novick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rele</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fargas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rele</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kharbeng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Araya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gervin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mavreas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lavrentzou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liontos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
              <collab>SOHO Study Group</collab>
            </person-group>
            <article-title>The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2003</year>
            <issue>416</issue>
            <fpage>16</fpage>
            <page-range>16-23</page-range>
            <pub-id pub-id-type="pmid">12755850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erdelji&#x00107; Turk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ku&#x0010d;an</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vitezi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Massive Clozapine Overdose: What to Expect?</article-title>
            <source>Psychiatr Danub</source>
            <year>2020</year>
            <season>Autumn</season>
            <volume>32</volume>
            <issue>3-4</issue>
            <fpage>431</fpage>
            <page-range>431-433</page-range>
            <pub-id pub-id-type="pmid">33370743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jansman</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Crommelin</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>van Hout</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Meulenbelt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis in Clozapine Overdose.</article-title>
            <source>Drug Saf Case Rep</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">27747721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sackey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Possible Clozapine Overdose-Associated Thromboembolic Event.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>364</fpage>
            <page-range>364-366</page-range>
            <pub-id pub-id-type="pmid">28350573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19641.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choudry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Naeem</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ayub</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Barriers to using clozapine in treatment-resistant schizophrenia: systematic review.</article-title>
            <source>BJPsych Bull</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-16</page-range>
            <pub-id pub-id-type="pmid">30261942</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
